LAFEROBION® drops 5 ml antiviral, antiproliferative and immunomodulating effect

Laferobion - suppositories drops 5 ml

• Indication-
• -in the complex therapy of acute respiratory viral infections (ARVIs)

•  -seasonal epidemics
• 
  
• 
  
• Pharmacological properties
• Recombinant interferon alpha-2b is a highly purified water-soluble protein with a molecular weight of 19,300 da.
• 
  
• It has antiproliferative effect on tumor cells, and also has antiviral and immunomodulating effects. The action of interferon alpha-2b is manifested by binding to specific receptors on the cell surface membrane and initiating a complex of sequential intracellular reactions associated with the induction of a number of enzymes and the implementation of cellular functions, namely: suppressing virus replication in an infected cell and reducing tumor cell proliferation; with the implementation of immunomodulatory processes (increased phagocytic activity of macrophages, increased specific cytotoxicity of lymphocytes to target cells).
• 
  
• Indications
• The drug is used in complex therapy in adults and children with:
• 
  
• acute and chronic viral hepatitis B (moderate and severe forms);
• chronic hepatitis C;
• acute and chronic septic diseases of a viral nature;
• acute viral, bacterial and mixed infections, including in newborns;
• acute and chronic septic diseases of viral and bacterial etiology, including the diminished forms of acute and chronic sepsis;
• herpes infections of various localization (herpes zoster, multiple skin herpetic eruptions, genital herpes, herpetic keratoconjunctivitis and keratouveitis);
• laryngeal papillomatosis;
• multiple sclerosis;
• malignant melanoma, uveal melanoma, renal cell carcinoma, superficially localized bladder cancer, ovarian and breast cancer, Kaposi’s sarcoma due to HIV infection, chronic myelogenous leukemia, hairy cell leukemia, non-Hodgkin’s lymphoma, basal cell carcinoma, lymphoma cell carcinoma, mycosis).
• Application
• The drug is used in the form of a solution. Laferobion solution is administered intravenously (drip), intramuscularly, subcutaneous, intradermally, intraperitoneally, intravesical, rectal, intranasal, subconjunctival.
• 
  
• Laferobion 100,000 IU for Intranasal Use
• 
  
• SARS in children, including newborns
• 
  
• Intranasally, 4–6 drops in each nasal passage 3–6 times a day for 3–5 days; the dosage of the drug for newborns is 20,000-50,000 IU / ml, for other children - 100,000 IU / ml. It is permissible to introduce into the nasal passages (alternately) cotton turundas moistened with Laferobion solution for 10-15 minutes.
• 
  
• SARS in adults
• 
  
• Intranasally 0.25 ml of Laferobion solution (100,000 ME / ml) in each nasal passage 6-8 times a day. Before use, the administered Laferobion solution should be heated in a syringe (use a syringe without a needle) to body temperature, the remainder of the solution should be stored in the refrigerator, protecting from bacterial contamination.
•